易明医药(002826) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was CNY 186,434,809.99, representing a 17.84% increase compared to CNY 158,204,489.91 in the same period last year[3] - Net profit attributable to shareholders for Q1 2022 was CNY 8,528,415.37, a significant increase of 62.16% from CNY 5,259,104.57 in Q1 2021[3] - Net profit for the period was CNY 8,639,617.30, representing a 64.4% increase from CNY 5,259,104.57 in Q1 2021[20] - The company reported a total comprehensive income of CNY 8,637,294.56 for the quarter, compared to CNY 5,265,796.80 in the same period last year[21] - Earnings per share (EPS) for the quarter was CNY 0.04, compared to CNY 0.03 in the previous year[21] Cash Flow - The net cash flow from operating activities improved to -CNY 5,190,203.15, a 47.09% reduction in losses compared to -CNY 9,808,758.10 in the previous year[3] - Cash flow from operating activities showed a net outflow of CNY -5,190,203.15, an improvement from CNY -9,808,758.10 in the same quarter last year[23] - Net cash flow from operating activities increased by 4,618,600 yuan compared to the same period last year, driven by performance growth[9] - Net cash flow from investing activities decreased by 32,166,600 yuan year-on-year, mainly due to the purchase of short-term principal-protected financial products amounting to 50 million yuan[9] - The net cash flow from investment activities was -51,446,057.00, indicating a significant outflow compared to the previous period[24] Assets and Liabilities - The company's total assets increased by 1.34% to CNY 835,486,086.66 from CNY 824,473,281.11 at the end of the previous year[3] - Total liabilities of the company were CNY 106,547,197.12, compared to CNY 104,362,512.05 in the previous period[20] - The total equity attributable to shareholders of the parent company was CNY 726,106,208.19, an increase from CNY 717,389,579.34[20] - Cash and cash equivalents decreased from 182,725,241.42 yuan at the beginning of the year to 126,392,276.12 yuan by the end of the reporting period[16] - The total cash and cash equivalents at the end of the period were 125,332,253.38, down from 181,970,809.43 at the beginning of the period[24] Expenses - Research and development expenses decreased by 79.64% to CNY 1,027,543.70, as the previous year's project concluded[8] - Research and development expenses decreased to CNY 1,027,543.70 from CNY 5,046,997.60, indicating a significant reduction in R&D spending[20] - Sales expenses increased by 52.97% to CNY 57,372,964.22, driven by higher marketing and promotional activities[8] - Sales expenses increased to CNY 57,372,964.22, up from CNY 37,506,799.99, marking a rise of 53.0% year-over-year[20] Accounts Receivable and Impairment - Accounts receivable increased by 179.21% to CNY 102,254,279.28, primarily due to changes in sales management and settlement methods[7] - Accounts receivable increased significantly from 36,622,988.75 yuan at the beginning of the year to 102,254,279.28 yuan by the end of the reporting period[16] - Credit impairment losses increased by 759,000 yuan year-on-year, primarily due to an increase in receivables and the corresponding increase in credit impairment losses[9] Shareholder Information - The company had a total of 16,982 common shareholders at the end of the reporting period[11] - The largest shareholder, Gao Fan, holds 26.66% of the shares, with 20,486,000 shares pledged[11] Other Income and Subsidies - The company received government subsidies amounting to CNY 563,592.94 related to employee training during the reporting period[5] - The company reported a significant increase in other income, which rose by 341.95% to CNY 570,349.21, reflecting improved operational performance[8] Financial Management - The company has no plans for future high-risk entrusted financial management as of the reporting period[15] - The company did not undergo an audit for the first quarter report[25]